The commonly sold antacid drug Ranitidine may soon be taken out of the government’s list of essential drugs. After this, the most sought-after anti-diabetic drug Teneligliptin can be included in this list.
The central government may soon release the new NLEM list. According to official sources, 26 items have been deleted from the upcoming NLEM, while 34 new items have been added.
An expert committee under the Indian Council of Medical Research (ICMR) submitted a revised list of 399 formulations last year and the list was released by the government in September 2021. Then Union Health Minister Mansukh Mandaviya demanded major changes on this.
The salt in ranitidine, sold under popular brands such as Zinetac and Rantac, has been questioned around the world after several cancer-related reports surfaced. In India, doctors widely recommend Ranitidine in the treatment of acid-related phlegm, dyspepsia, abdominal pain and heartburn.
With concerns about the safety of the products rising in the Indian market too, the Health Ministry is in discussion with the Drug Controller General of India and the All India Institute of Medical Sciences (AIIMS) to take this salt out of the stock of essential medicines in the country.
Gliptins used in the treatment of type 2 diabetes may be included in the new list. While the gliptin market in India is more than Rs 4,000 crore, the market value of Teneligliptin is Rs 1,000 crore. Their biggest manufacturer is Glenmark.
Also Read – International Indigenous day 2022: Everything You Need To Know
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
